Order Requires Valsartan Recall Lawsuits To Provide Product Identification for Specific Generic Drug Makers Named
Sports Betting Addiction Lawsuit Sports betting addiction lawsuits are being investigated for college students and young adults who developed gambling problems after using apps like FanDuel and DraftKings, alleging that the platforms failed to warn about the addictive nature of their features and marketing practices.
Nitrous Oxide Lawsuit Individuals who suffered harm, or families who lost a loved one after using nitrous oxide products may be eligible for financial compensation through a nitrous oxide lawsuit.
Hair Relaxer Lawsuit Regular exposure to chemicals in hair relaxer may cause uterine cancer, ovarian cancer and other injuries. Women diagnosed with cancer may be eligible for settlement benefits.
Depo-Provera Lawsuit Depo-Provera lawsuits are being investigated for women who developed meningioma brain tumors after receiving Depo-Provera birth control shots, claiming that Pfizer failed to adequately disclose side effects.
Ozempic Lawsuit Lawyers are pursuing Ozempic lawsuits, Wegovy lawsuits and Mounjaro lawsuits over gastroparesis or stomach paralysis, which can leave users with long-term gastrointestinal side effects
Suboxone Tooth Decay Lawsuit Lawsuits are being pursued by users of Suboxone who experienced tooth loss, broken teeth or required dental extractions. Settlement benefits may be available.
Change Healthcare Lawsuit Lawyers are reviewing Change Healthcare class action lawsuits for individuals who had their personal information stolen due to the data breach.
Bard PowerPort Lawsuit Serious and life-threatening injuries have been linked to problems with Bard PowerPort. Lawsuits are now being pursued by individuals who suffered injuries from the implantable port catheter fracturing or migrating.
AngioDynamics Port Catheter Lawsuit Serious and life-threatening injuries have been linked to problems with Bard PowerPort. Lawsuits are now being pursued by individuals who suffered injuries from the implantable port catheter fracturing or migrating.
Processed Food Lawsuit Lawsuits are being pursued against the food industry over their manufacturing and advertising of ultra-processed foods, which have caused a generation of children to face an increased risk of developing childhood diabetes and other chronic illnesses.
Mylan Valsartan Recall Expanded As More Lots Found To Be Contaminated With NDEA December 6, 2018 Irvin Jackson Add Your Comments Another batch of generic valsartan medications are being recalled, due to manufacturing problems that may have resulted in cancer-causing impurities contaminating the drugs. Mylan has expanded a valsartan recall issued after trace amounts of N-nitrosodiethylamine (NDEA) were found in the pharmaceutical ingredients. As a result, all lots of Mylan valsartan that have not expired are being recalled. While the drug manufacturer indicates that there have been no confirmed adverse events or cases of cancer diagnosed in connection with the recalled Mylan valsartan tablets, the impurity is a known human carcinogen, and may have tainted generic versions of the hypertension drug distributed for years. VALSARTAN LAWSUITS Were you prescribed contaminated Valsartan drugs? Side effects of recalled valsartan may increase the risk of cancer, due to an impurity discovered in certain generic versions of the hypertension drug. Learn More SEE IF YOU QUALIFY FOR COMPENSATION VALSARTAN LAWSUITS Were you prescribed contaminated Valsartan drugs? Side effects of recalled valsartan may increase the risk of cancer, due to an impurity discovered in certain generic versions of the hypertension drug. Learn More SEE IF YOU QUALIFY FOR COMPENSATION NDEA occurs naturally in certain foods and drinking water, but can be created as a byproduct of industrial processes, which is what the FDA believes occurred in this instance and with other recent valsartan recalls linked to the presence of a similar impurity, N-nitrosodimethylamine (NDMA). Both are considered probably cancer-causing agents by the International Agency for Research on Cancer (IARC). The original Mylan valsartan recall, issued on November 20, affected 15 lots of Mylan Pharmaceuticals, Inc. products containing valsartan, including Valsartan Tablets, Amiodipine and Valsartan Tablets, and Valsartan and Hydrochlorothiazide Tablets. The expansion affects an additional 104 lots, including 51 lots of Valsartan Tablets, 26 lots of Amlodipine and Valsartan Tablets, and 27 lots of Valsartan and Hydrochlorothiazide Tablets. The recalled products were distributed in the U.S. between March 2017 and November 2018. The lots involved the use of batches of tainted valsartan manufactured by Mylan Pharmaceuticals, Inc. and Mylan Laboratories Limited. The company indicates it is notifying distributors and customers by letter and arranging for the return of the recalled products. The recall notice advises wholesalers, retailers and consumers in possession of recalled products to contact Stericycle by calling 1-888-406-9305 to arrange for the return of the products. Valsartan Cancer Concerns The announcement is the latest in a string of ongoing recalls affecting valsartan and other hypertension drugs which may be contaminated with NDMA or NDEA; impurities created during the manufacturing process. The first valsartan problems surfaced on July 5, after European regulators announced that batches of the active ingredient supplied by Zhejiang Huahai Pharmaceuticals tested positive for NDMA. The FDA followed with its own recall announcement on July 13, indicating that the agency had launched an investigation to determine the scope of the contamination and the potential risk to consumers. In late September, the FDA stopped all imports of drug ingredients and medicines made by Zhejiang Huahai Pharmaceuticals, after an inspection report outlined a number of serious manufacturing problems at the company’s facility in late August. The recalls have led to a valsartan shortage and a spike in prices, with the cost of 160 milligram and 80 milligram tablets of generic valsartan more than doubling in September 2018. As consumers nationwide continue to face concerns about the safety of pills they have taken in recent years, a number of valsartan recall class action lawsuits have been filed nationwide, seeking damages for the cost of the recalled drugs and medical monitoring. For those diagnosed with liver cancer, kidney cancer, pancreatic cancer, stomach cancer and other cancers, individual cases are being reviewed by valsartan lawyers. The FDA has assigned a group of pharmacists and nurses to answer consumer’s questions about the recalls. Since the first recalls, the agency indicates it has received more than 6,000 inquiries from patients, doctors, nurses, pharmacists and academics. Inquiries can be made by calling 855-543-3784 or by sending an email to druginfo@fda.hhs.gov. Consumers are urged to contact their doctor if they have experienced any problems that may be related to the recalled valsartan. Healthcare professionals and patients are urged to report adverse events to FDA’s MedWatch adverse event reporting program. Tags: Cancer, Drug Recall, Mylan Pharmaceuticals, NDEA, Valsartan More Valsartan Lawsuit Stories Court Outlines Valsartan Lawsuits Trial Schedule for “Wave 2” Bellwether Cases May 28, 2025 Order Requires Valsartan Recall Lawsuits To Provide Product Identification for Specific Generic Drug Makers Named March 27, 2025 Deadlines Leading to First Valsartan Bellwether Trial on Sept. 8, 2025 Outlined by Special Master March 4, 2025 0 Comments Share Your CommentsFirst Name*Last NameEmail* Shared Comments*This field is hidden when viewing the formI authorize the above comments be posted on this page Yes No Post Comment I authorize the above comments be posted on this page Weekly Digest Opt-In Yes, send me a weekly email with the latest lawsuits, recalls and warnings. Want your comments reviewed by a lawyer?To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.Contact Phone #Alt Phone #Private CommentsNOTE: Providing information for review by an attorney does not form an attorney-client relationship.CAPTCHAGA SourceGA CampaignGA MediumGA ContentGA TermEmailThis field is for validation purposes and should be left unchanged. Δ MORE TOP STORIES Depo-Provera Wrongful Death Lawsuit Blames Injections for Fatal Brain Tumor (Posted: today) A wrongful death lawsuit claims a woman’s sister died of a Depo-Provera brain tumor which was not discovered until after her death. MORE ABOUT: DEPO-PROVERA LAWSUITLawsuit Alleges Depo-Provera DMPA Injection Increases Brain Tumor Risks (06/20/2025)Ortho-Cept, Similar Birth Control Pills Linked to Intracranial Meningioma Risks, Study Warns (06/17/2025)Status of Depo-Provera Shot Lawsuits Outlined by MDL Judge (06/13/2025) 12 Hair Dye Lawsuits Over Bladder Cancer Risks Assigned to One Judge in California State Court (Posted: yesterday) A dozen hair dye lawsuits over bladder cancer risks have been consolidated under one California state judge for coordinated pretrial proceedings. MORE ABOUT: HAIR DYE LAWSUITJudge To Meet With Hair Dye Lawyers in Bladder Cancer Lawsuit for Initial Status Conference (06/16/2025)Lawsuit Claims Paul Mitchell, Redken, Other Hair Dyes Led to Bladder Cancer Diagnosis for Hairdresser (05/09/2025)Salon Stylist Files Lawsuit Over Bladder Cancer From Hair Dye Products (05/02/2025) BioZorb Implant Removal Surgery: What Women Need To Know When the Device Fails To Dissolve (Posted: 2 days ago) Following a Class I recall, more than 100 BioZorb lawsuits have been filed by breast cancer survivors who suffered painful complications after the surgical tissue marker failed to dissolve as intended. MORE ABOUT: BIOZORB LAWSUITLawsuit Claims Biozorb Implant Penetrated Skin, Causing Massive Infection (06/04/2025)Breast Cancer Survivors File BioZorb Tissue Marker Lawsuit After Implant Fails (05/20/2025)BioZorb Implant Lawsuit Alleges Tissue Marker Caused Swelling, Fluid Buildup and Chronic Pain (05/14/2025)
Order Requires Valsartan Recall Lawsuits To Provide Product Identification for Specific Generic Drug Makers Named March 27, 2025
Deadlines Leading to First Valsartan Bellwether Trial on Sept. 8, 2025 Outlined by Special Master March 4, 2025
Depo-Provera Wrongful Death Lawsuit Blames Injections for Fatal Brain Tumor (Posted: today) A wrongful death lawsuit claims a woman’s sister died of a Depo-Provera brain tumor which was not discovered until after her death. MORE ABOUT: DEPO-PROVERA LAWSUITLawsuit Alleges Depo-Provera DMPA Injection Increases Brain Tumor Risks (06/20/2025)Ortho-Cept, Similar Birth Control Pills Linked to Intracranial Meningioma Risks, Study Warns (06/17/2025)Status of Depo-Provera Shot Lawsuits Outlined by MDL Judge (06/13/2025)
12 Hair Dye Lawsuits Over Bladder Cancer Risks Assigned to One Judge in California State Court (Posted: yesterday) A dozen hair dye lawsuits over bladder cancer risks have been consolidated under one California state judge for coordinated pretrial proceedings. MORE ABOUT: HAIR DYE LAWSUITJudge To Meet With Hair Dye Lawyers in Bladder Cancer Lawsuit for Initial Status Conference (06/16/2025)Lawsuit Claims Paul Mitchell, Redken, Other Hair Dyes Led to Bladder Cancer Diagnosis for Hairdresser (05/09/2025)Salon Stylist Files Lawsuit Over Bladder Cancer From Hair Dye Products (05/02/2025)
BioZorb Implant Removal Surgery: What Women Need To Know When the Device Fails To Dissolve (Posted: 2 days ago) Following a Class I recall, more than 100 BioZorb lawsuits have been filed by breast cancer survivors who suffered painful complications after the surgical tissue marker failed to dissolve as intended. MORE ABOUT: BIOZORB LAWSUITLawsuit Claims Biozorb Implant Penetrated Skin, Causing Massive Infection (06/04/2025)Breast Cancer Survivors File BioZorb Tissue Marker Lawsuit After Implant Fails (05/20/2025)BioZorb Implant Lawsuit Alleges Tissue Marker Caused Swelling, Fluid Buildup and Chronic Pain (05/14/2025)